Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

RedHill Biopharma Announces Positive DSMB Review for Phase 2/3 COVID-19 Study of Opaganib

americanpharmaceuticalreviewFebruary 04, 2021

Tag: opaganib , RedHill , COVID-19 , DSMB

PharmaSources Customer Service